Compare ARMP & LNSR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARMP | LNSR |
|---|---|---|
| Founded | N/A | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical Electronics |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.7M | 136.8M |
| IPO Year | N/A | N/A |
| Metric | ARMP | LNSR |
|---|---|---|
| Price | $6.42 | $12.35 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 1 |
| Target Price | $12.00 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 54.2K | 32.9K |
| Earning Date | 03-19-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $5,054,000.00 | ★ $59,141,000.00 |
| Revenue This Year | $4.48 | $19.55 |
| Revenue Next Year | N/A | $35.89 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 21.02 |
| 52 Week Low | $0.90 | $8.96 |
| 52 Week High | $16.34 | $17.31 |
| Indicator | ARMP | LNSR |
|---|---|---|
| Relative Strength Index (RSI) | 51.52 | 61.22 |
| Support Level | $5.75 | $12.12 |
| Resistance Level | $6.37 | $12.85 |
| Average True Range (ATR) | 0.74 | 0.32 |
| MACD | -0.02 | 0.05 |
| Stochastic Oscillator | 33.19 | 63.50 |
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
LENSAR Inc is a commercial-stage medical device company focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, simplified procedure planning, efficient design, and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. Geographically, the company generates the majority of its revenue from the United States, followed by Europe and Asia.